What is the treatment for Iron Deficiency Anemia (IDA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Iron Deficiency Anemia (IDA)

Oral iron supplementation is the first-line treatment for most patients with iron deficiency anemia, with ferrous sulfate 200 mg twice daily being the most effective and economical option to correct anemia and replenish iron stores. 1

Initial Treatment Approach

  • All patients with IDA should receive iron supplementation to correct anemia and replenish body stores, regardless of the underlying cause 1
  • First-line therapy is oral ferrous sulfate 200 mg twice daily (contains approximately 65 mg elemental iron per tablet) 1
  • Alternative oral iron formulations may be better tolerated in some patients:
    • Ferrous fumarate or ferrous gluconate may cause fewer gastrointestinal side effects 1
    • Liquid preparations can be used when tablets are not tolerated 1
  • Lower doses of oral iron may be as effective and better tolerated than traditional doses 1

Duration of Treatment

  • Oral iron should be continued for 3 months after correction of anemia to ensure iron stores are fully replenished 1
  • Hemoglobin concentration should rise by approximately 2 g/dL after 3-4 weeks of proper treatment 1
  • Failure to respond suggests poor compliance, misdiagnosis, continued blood loss, or malabsorption 1

Adjunctive Therapies

  • Ascorbic acid (250-500 mg twice daily) taken with iron supplements may enhance iron absorption when response to iron therapy is poor 1
  • Treatment of any underlying cause (e.g., gastrointestinal bleeding, celiac disease) should be addressed simultaneously to prevent further iron loss 1

Intravenous Iron Therapy

Intravenous (IV) iron should be considered in the following situations:

  • Intolerance to at least two oral iron preparations 1
  • Non-compliance with oral therapy 1
  • Patients with inflammatory bowel disease and active inflammation with compromised absorption 1
  • Patients with portal hypertensive gastropathy and ongoing bleeding who don't respond to oral iron 1
  • Severe iron deficiency requiring rapid repletion 2

Available IV iron preparations include:

  • Iron sucrose (Venofer) - can be administered as 200 mg over 10 minutes 1, 3
  • Ferric carboxymaltose (Ferinject) - can deliver up to 1000 mg in a single 15-minute infusion 1
  • Iron dextran (Cosmofer) - can be given IV or IM, but carries higher risk of serious reactions 1

Special Populations

  • Inflammatory Bowel Disease: IV iron therapy is preferred in patients with active inflammation due to compromised absorption of oral iron 1
  • Portal Hypertensive Gastropathy: Start with oral iron, but switch to IV iron if there's ongoing bleeding without response to oral therapy 1
  • Celiac Disease: Ensure adherence to a gluten-free diet to improve iron absorption; consider IV iron if stores don't improve with oral therapy 1
  • Small-bowel Angioectasias: Iron replacement (oral or IV depending on severity) should accompany endoscopic treatment 1

Monitoring and Follow-up

  • Monitor hemoglobin concentration and red cell indices at regular intervals:
    • Every 3 months for the first year after correction
    • Then after a further year 1
  • Additional oral iron should be given if hemoglobin or MCV falls below normal 1
  • Further investigation is only necessary if hemoglobin and MCV cannot be maintained with supplementation 1

Common Pitfalls and Caveats

  • Failure to continue iron therapy for 3 months after normalization of hemoglobin leads to inadequate replenishment of iron stores 1
  • Accepting upper GI findings like erosions or peptic ulcers as the sole cause of IDA without investigating the lower GI tract (dual pathology occurs in 10-15% of patients) 1
  • Overlooking poor compliance due to gastrointestinal side effects of oral iron 1
  • Parenteral iron therapy should not be used routinely due to higher cost and risk of adverse reactions, including rare but serious anaphylactic reactions 1
  • Transfusions should be avoided in chronically anemic patients due to potential side effects and cost, and reserved only for hemodynamically unstable patients 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of iron deficiency.

Hematology. American Society of Hematology. Education Program, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.